Underwriting AgreementUnderwriting Agreement • July 10th, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • New York
Replimune Group, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [·] shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [·] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 10th, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”), dated as of [ ], is by and between Replimune Group, Inc., a Delaware corporation (the “Company”) and [NAME OF DIRECTOR/OFFICER](1) (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 10th, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. (the “Company”) and Howard Kaufman (the “Executive”) as of June 22, 2018.
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • July 10th, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into effective as of the date signed by the last Party to sign below (the “Effective Date”) by and between Replimune Inc., a corporation organized under the laws of Delaware, having a place of business at 18 Commerce Way, Woburn, MA 01801 (the “Recipient”) and Bristol-Myers Squibb Company, having a place of business at 345 Park Avenue, New York, NY 10154 (“BMS”). The Recipient and BMS are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
THIS AGREEMENT is made on 16 September 2015Agreement • July 10th, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • England and Wales
